---
title: "GeoVax Labs, Inc. (GOVX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GOVX.US.md"
symbol: "GOVX.US"
name: "GeoVax Labs, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T09:49:28.977Z"
locales:
  - [en](https://longbridge.com/en/quote/GOVX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GOVX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GOVX.US.md)
---

# GeoVax Labs, Inc. (GOVX.US)

## Company Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.geovax.com](https://www.geovax.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: E (0.85)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 370 / 387 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -84.76% |  |
| Net Profit YoY | 12.78% |  |
| P/B Ratio | 12.95 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6392579.70 |  |
| Revenue | 852282.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -509.28% | E |
| Profit Margin | -2507.27% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -84.76% | E |
| Net Profit YoY | 12.78% | C |
| Total Assets YoY | -72.47% | E |
| Net Assets YoY | -93.75% | E |
| Cash Flow Margin | 89.13% | C |
| OCF YoY | -84.76% | E |
| Turnover | 0.12 | E |
| Gearing Ratio | 83.44% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - GeoVax Labs, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-84.76%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "12.78%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "12.95",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6392579.70",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "852282.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-509.28%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2507.27%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-84.76%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "12.78%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-72.47%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-93.75%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "89.13%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-84.76%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.12",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "83.44%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.30 | 109/387 | - | - | - |
| PB | 12.95 | 402/387 | 7.04 | 4.25 | 0.87 |
| PS (TTM) | 7.50 | 145/387 | 3.01 | 2.43 | 1.27 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Vaxart (VXRT.US) | A | A | A | C | B | A |
| 05 | Spero Therap (SPRO.US) | A | A | B | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.21 |
| Highest Target | 212.50 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GOVX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GOVX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GOVX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GOVX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**